IXICO PLC — Share Issue/Capital Change 2018

Jun 7, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6412Q

IXICO plc

07 June 2018

7 June 2018

IXICO plc

("IXICO" or the "Company")

Issue of Equity

The Company announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 15,000 new ordinary shares of 0.1p each ("New Shares") to satisfy the exercise of options granted under the IXICO EMI Share Option Plan 2014.

The New Shares are expected to be admitted to trading on AIM on 13 June 2018.

Total voting rights

Application has been made for admission to trading on AIM of 15,000 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 13 June 2018, following which there will be in total 46,776,986 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

For further information please contact:

IXICO plc Giulio Cerroni, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker) Edward Mansfield / Anita Ghanekar / Daniel Bush	Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan	Tel: +44 20 3727 1000

About IXICO

IXICO is the digital technologies company serving neuroscience. Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global pharmaceutical industry to select participants for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable sponsors to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOELIFSTREIDIIT